Actively Recruiting
Phase 1 Study of S-892216 Long-acting Injectable in Healthy Adults Evaluating Single and Multiple Doses
Led by Shionogi · Updated on 2026-10-16
128
Participants Needed
3
Research Sites
N/A
Total Duration
AI-Summary
What This Trial Is About
Researchers are studying the safety, tolerability, and how the body processes pharmacokinetics a long-acting injectable drug called S-892216-LAI in healthy adults. This Phase 1 trial involves participants aged 18 to 55 years to better understand the effects of single and multiple doses of this investigational drug compared to a placebo. Participants will receive either a single dose of S-892216-LAI or placebo on Day 1 in the first treatment period. In the second treatment period, participants will receive multiple doses on Day 1 and Day 85. The study uses a randomized, parallel design and includes a placebo control with quadruple masking to keep the treatment assignment confidential. During the study, participants will be monitored closely for any treatment-emergent adverse events from Day 1 through up to Day 448, depending on the treatment period. Researchers will measure the drug and its metabolites in the blood at various timepoints to assess concentration levels and how quickly the drug reaches its maximum concentration. Participants will undergo regular evaluations for safety and drug levels over the course of the study, which may last up to approximately 15 months.
CONDITIONS
Brief Title
Study of S-892216 Long-acting Injectable (LAI) in Healthy Adult Participants
Research Team
S
Shionogi Clinical Trials Administrator Clinical Support Help Line
Not the Right Trial for You?
Explore thousands of other clinical trials that might be a better match.
Sign up to get personalized trial recommendations delivered to your inbox.
Already have an account? Log in here